HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $106,578 | +10.7% | 2,790 | +4.6% | 0.01% | +10.0% |
Q2 2023 | $96,235 | +143.7% | 2,668 | +158.0% | 0.01% | +150.0% |
Q1 2023 | $39,489 | -27.7% | 1,034 | +7.7% | 0.00% | -33.3% |
Q4 2022 | $54,624 | +203.5% | 960 | +111.5% | 0.01% | +200.0% |
Q3 2022 | $18,000 | -10.0% | 454 | +0.4% | 0.00% | -33.3% |
Q2 2022 | $20,000 | +42.9% | 452 | +25.9% | 0.00% | +50.0% |
Q1 2022 | $14,000 | +55.6% | 359 | +56.1% | 0.00% | +100.0% |
Q4 2021 | $9,000 | +50.0% | 230 | +46.5% | 0.00% | 0.0% |
Q3 2021 | $6,000 | 0.0% | 157 | +26.6% | 0.00% | 0.0% |
Q2 2021 | $6,000 | +20.0% | 124 | +2.5% | 0.00% | 0.0% |
Q1 2021 | $5,000 | 0.0% | 121 | +12.0% | 0.00% | 0.0% |
Q4 2020 | $5,000 | +66.7% | 108 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $3,000 | 0.0% | 108 | +14.9% | 0.00% | 0.0% |
Q2 2020 | $3,000 | -91.7% | 94 | -95.4% | 0.00% | -83.3% |
Q1 2020 | $36,000 | +2.9% | 2,053 | +0.5% | 0.01% | +50.0% |
Q4 2019 | $35,000 | +483.3% | 2,042 | +476.8% | 0.00% | 0.0% |
Q4 2015 | $6,000 | – | 354 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |